Reata - RETA EV/EBITDA Multiple

Corporate emblem and logo of Reata (RETA)

Reata Pharmaceuticals (RETA) has earned its status as a savior by developing the first drug to treat Friedreich's ataxia. The company's EV/EBITDA multiple, as shown on the GURU.Markets chart, demonstrates a stable balance between valuation and earnings, with the latest parameter standing at . While assets are currently scaling through Biogen resources, international conflicts could hinder global trials and patent protection.

RETA (Reata) EV/EBITDA Multiple history from 07/04/2022 to 11/12/2026

RETA (reatapharma.com): analytical breakdowns and indicator data

- market price and analyst price targets:
Price Chart Reata|RETA - Broker Consensus Forecast
- issuer market value details:
Market Capitalization Reata Pharma|RETA - Total Enterprise Value
- issuer book value statistics:
Accounting Value per Share Reata Pharmaceuticals|RETA - Book Capitalization|Market Value to Book Value Ratio reatapharma.com|RETA - Aggregate Asset Value
- debt and liquidity data:
Debt to Equity Reata Pharmaceuticals|RETA - Long-Term Liabilities to Capital|Short-Term Debt to Equity Reata Pharmaceuticals, Inc.|RETA - Company Debts|Debt to Book Capitalization Ratio Reata Pharma|RETA - Long-Term Debt|Company Short-Term Debts Reata Pharmaceuticals|Quick Liquidity Indicator reatapharma.com
- net income and valuation multiples indicators:
RETA - Company Net Income|Expected Profit Reata Pharmaceuticals|RETA - Company Value to Net Income|Forward P/E Multiple Reata Pharmaceuticals|RETA - Price to Earnings Adjusted for Growth Rate|EV/EBITDA Multiple Reata Pharma|RETA - Operating profit EBITDA|Net earnings per share for the last 12 months Reata Pharmaceuticals|RETA - Earnings per share for the last four quarters|Quarterly EPS earnings growth reatapharma.com|RETA - Earnings growth in current year|Expected earnings per share growth for next year Reata Pharmaceuticals
Summary company analytics:RETA (Reata)
Original product of Reata Pharmaceuticals, Inc.

The market capitalization of Reata Pharmaceuticals (RETA) depends on the market penetration of Skyclarys and the effectiveness of insurance coverage within the orphan drug segment. The business's EV/EBITDA multiple compares the total enterprise value, including net debt, against its operating profitability before depreciation and amortization, excluding the impact of tax regimes. A decrease in this ratio signals that the company is undervalued, whereas its growth indicates that the asset is overbought.

Competitor analysis

Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Jazz Pharma JAZZ|CYTK: Enterprise Value to Operating Income Before Depreciation|PTC Therapeutics, Inc. - EV/EBITDA Multiple|Company Value to EBITDA scholarrock.com|CNTA (Centessa) - Enterprise Value to EBITDA Ratio|Dyne Therapeutics Inc (DYN) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Edgewise Pharma|RAPP: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Alumis Inc. (ALMS)|ZVRA - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Contineum Therapeutics CTNM|Larimar Therapeutics Inc - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CAPR - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Entrada Therapeutics, Inc|PTHS: EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple MediciNova MNOV|Enterprise Value to EBITDA Ratio SER|Company Value to EBITDA BioXcel Therapeutics Inc BTAI|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ProMIS Neurosciences (PMN)|APUS (apimedsus.com) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple AEON (AEON Biopharma, Inc.)|NLS Pharmaceutics Ltd. (NLSP) - Company Value to EBITDA|Bionomics Ltd - EV/EBITDA Multiple|HUGE - EV/EBITDA Multiple